openPR Logo
Press release

Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Market Size, Prevalence, Therapies and Companies by DelveInsight | Eli Lilly, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG

09-11-2024 05:58 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Chronic Lower Back Pain Treatment Market

Chronic Lower Back Pain Treatment Market

(Albany, USA) DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Lower Back Pain Market Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Chronic Lower Back Pain Market Report:
• The Chronic Lower Back Pain market size was valued approximately USD 6,227 Million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were a total of 77,300,000 prevalent cases of CLBP in 2022. It is anticipated that there would be an increase in CLBP patients in the 7MM from 2019 to 2032
• Spain had the highest prevalence of CLBP cases in the EU4 with 8,930,000 cases, followed by the UK with 6,040,000 cases in 2022
• In 2022, there were 12,700,000 cases of Chronic Lower Back Pain in Japan.
• In February 2023, Camurus withdrew the CAM2038 application once it was expanded to cover chronic pain.
• In February 2023, Rexlemestrocel-L was given the RMAT designation by the FDA for regenerative medicine advanced therapy (chronic lower back pain).
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• The Chronic Lower Back Pain epidemiology based on gender analyzed that most of the CLBP cases include female population as compared to male patient pool
• The Chronic Lower Back Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Lower Back Pain pipeline products will significantly revolutionize the Chronic Lower Back Pain market dynamics.
• In August 2024, Eli lilly announced results of a Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain (Drug: LY3016859 ISA; Drug: LY3556050 ISA; Drug: LY3526318 ISA; Drug: LY3857210 ISA)
• In July 2024, Mesoblast announced results of a Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain

Chronic Lower Back Pain Overview
Chronic lower back pain (CLBP) refers to pain that persists for 12 weeks or longer, even after an initial injury or underlying cause has been treated. It is one of the most common health problems globally and can significantly impair daily functioning and quality of life. The pain may be continuous or intermittent and can range from a dull ache to a sharp, stabbing sensation. Common causes of CLBP include herniated discs, spinal stenosis, degenerative disc disease, and muscle or ligament strain. In some cases, no specific cause is identified.

Risk factors include aging, obesity, physical inactivity, poor posture, and occupations that involve heavy lifting or prolonged sitting. CLBP can also be exacerbated by psychological factors such as stress, anxiety, and depression.

Treatment typically involves a combination of pain relief methods, including physical therapy, medications like NSAIDs, and lifestyle changes such as weight management and exercise. In severe cases, surgery may be considered. Prevention strategies focus on maintaining a healthy weight, regular physical activity, and proper posture. Managing CLBP requires a multidisciplinary approach to improve mobility, reduce discomfort, and enhance the overall quality of life.

Get a Free sample for the Chronic Lower Back Pain Market Report:
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Lower Back Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Lower Back Pain Epidemiology Segmentation:
The Chronic Lower Back Pain market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Chronic Lower Back Pain
• Prevalent Cases of Chronic Lower Back Pain by severity
• Gender-specific Prevalence of Chronic Lower Back Pain
• Diagnosed Cases of Episodic and Chronic Chronic Lower Back Pain

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Lower Back Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Lower Back Pain Therapies and Key Companies
• LY3016859: Eli Lilly and Company
• Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
• Semdexa (SP-102): Scilex Holding
• Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
• AMG0103: AnGes MG, Inc
• Duloxetine: Eli Lilly and Company
• buprenorphine: Braeburn Pharmaceuticals
• Celebrex 200mg: Pfizer
• Oxymorphone ER: Endo Pharmaceuticals
• PP353: Persica Pharmaceuticals
• Oxycodone DETERx: Collegium Pharma
• Bicifadine: DOV Pharma
• OROS hydromorphone: Mallinckrodt
• EN3324 (axomadol): Grünenthal GmbH
• ABT-712: AbbVie

Discover more about therapies set to grab major Chronic Lower Back Pain market share @ Chronic Lower Back Pain Treatment Market
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Chronic Lower Back Pain Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• Chronic Lower Back Pain Therapeutic Assessment: Chronic Lower Back Pain current marketed and Chronic Lower Back Pain emerging therapies
• Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and Chronic Lower Back Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Lower Back Pain Unmet Needs, KOL's views, Analyst's views, Chronic Lower Back Pain Market Access and Reimbursement

To know more about Chronic Lower Back Pain companies working in the treatment market, visit @ Chronic Lower Back Pain Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Chronic Lower Back Pain Market Report Introduction
2. Executive Summary for Chronic Lower Back Pain
3. SWOT analysis of Chronic Lower Back Pain
4. Chronic Lower Back Pain Patient Share (%) Overview at a Glance
5. Chronic Lower Back Pain Market Overview at a Glance
6. Chronic Lower Back Pain Disease Background and Overview
7. Chronic Lower Back Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Lower Back Pain
9. Chronic Lower Back Pain Current Treatment and Medical Practices
10. Chronic Lower Back Pain Unmet Needs
11. Chronic Lower Back Pain Emerging Therapies
12. Chronic Lower Back Pain Market Outlook
13. Country-Wise Chronic Lower Back Pain Market Analysis (2019-2032)
14. Chronic Lower Back Pain Market Access and Reimbursement of Therapies
15. Chronic Lower Back Pain Market Drivers
16. Chronic Lower Back Pain Market Barriers
17. Chronic Lower Back Pain Appendix
18. Chronic Lower Back Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-bronchitis-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Progressive Multiple Sclerosis Market: https://www.delveinsight.com/report-store/chronic-progressive-multiple-sclerosis-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-market
• Encephalitis Market: https://www.delveinsight.com/report-store/encephalitis-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Bacteremia Market: https://www.delveinsight.com/report-store/bacteremia-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Cardiac Insufficiency Market: https://www.delveinsight.com/report-store/congestive-heart-failure-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Refractory Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Egfr Non-small Cell Lung Cancer Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Lower Back Pain Treatment Market 2032: FDA Approval, Clinical Trials, Market Size, Prevalence, Therapies and Companies by DelveInsight | Eli Lilly, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG here

News-ID: 3651562 • Views:

More Releases from DelveInsight Business Research

Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies, Treatment Market, ROA, MOA and Companies involved by DelveInsight
Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA, PDMA, FDA Approval …
(Albany, USA) DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It
Acute Lymphocytic Leukemia Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, ROA, MOA and Companies involved by DelveInsight | Novartis, Jazz Pharmaceuticals, Takara Bio, Cellectis, AbbVie, vAutolus, Celgene
Acute Lymphocytic Leukemia Clinical Trials Assessment 2024: FDA Approvals, Pipel …
(Albany, USA) DelveInsight's, "Acute Lymphocytic Leukemia Pipeline Insight" report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this
Renal Cancer Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, Treatment Market, ROA, MOA and Companies involved by DelveInsight
Renal Cancer Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies …
(Albany, USA) DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key
Diffuse Intrinsic Pontine Glioma Clinical Trial 2024: FDA Approvals, Pipeline, Therapies, ROA, MOA and Companies by DelveInsight | Kazia Therapeutics, Kintara Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene
Diffuse Intrinsic Pontine Glioma Clinical Trial 2024: FDA Approvals, Pipeline, T …
(Albany, USA) DelveInsight's, "Diffuse Intrinsic Pontine Glioma Pipeline Insight" report provides comprehensive insights about 25+ Diffuse Intrinsic Pontine Glioma companies and 25+ pipeline drugs in the Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the Diffuse Intrinsic Pontine Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Intrinsic Pontine Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further

All 5 Releases


More Releases for Chronic

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Reviewed, …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market Res …
Latest industry research report on: Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData's clinical trial report, Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them
11-10-2016 | Health & Medicine
MRR.biz
Global Chronic, Acute, And Neuropathic Pain Market: Opioids To Remain Most Value …
The research report, titled “Frontier Pharma: Chronic, Acute And Neuropathic Pain - GPCR And Nerve Growth Factor-Based Therapies Offer Strong Potential In Difficult-To-Treat Subtypes,” analyzes the historical as well as the existing performance of this market, emphasizing specifically on various types of therapies applied to treat chronic, acute, and neuropathic pain. According to this 68-page study, the worldwide market for chronic, acute, and neuropathic pain has been observing a significant
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system. Pain is an important protection system of the human body. But when it becomes chronic, as it frequently